Investment: PPL prospects uncertain
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.CLONING DOLLY the sheep was all a bit of fun and earned PPL Therapeutics unprecedented attention from the media. But it is now time for the biotech company to turn to the serious business of developing drugs. The price of yesterday's heavily discounted rights issue, at 80p against the closing price of 112.5p, shows the going will be far from easy.
The company plans to spend the bulk of the pounds 20.4m raised in the six-for- five issue to fund development of BSSL, its cystic fibrosis and pancreatitis drug, and Factor IX, a haemophilia treatment, to be launched in 2002-3. These compounds, like all PPL's drugs, are derived from the milk of genetically engineered sheep such as Polly, Dolly's successor.
This is an innovative technology and could lead to the development of more user-friendly and less costly medicines. But does it work? The answer will come in the first quarter of next year, when PPL is due to publish the results of a trial for the anti-cystic fibrosis drug AAT, its most advanced and most promising product.
A positive result would also speed negotiations with two mystery pharmaceutical partners to launch AAT in 2001. If the sheep's milk technology is shown to work with AAT, then PPL with its focused pipeline, multi-million pound potential markets and reasonably good balance sheet, could become one of the biotech successes of the next millennium. If it fails, PPL will look fragile. Given the uncertainty over the company's prospects, the shares are no more than a hold.
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments